SinoMab BioScience Ltd (HKSE:03681) Share Price

Company Profile

Business description
SinoMab BioScience Ltd is a biopharmaceutical company. The company is engaged in the research, development, manufacturing, and commercialization of therapeutics for the treatment of immunological diseases, monoclonal antibody (mAb)-based biologics. Its flagship product, SM03 (Suciraslimab), is a potential global first-in target mAb for the treatment of rheumatoid arthritis (RA) and potentially for the treatment of other immunological diseases such as systemic lupus erythematosus (SLE), Sjogren’s syndrome (SS) as well as non-Hodgkin’s lymphoma (NHL), and other indications. The group derives revenue from Hong Kong.
Contact
No. 15 Science Park West Avenue
Units 303 and 305 to 307
Hong Kong Science Park, Pak Shek Kok
New Territories
Hong Kong
HKG
T: +852 34269833
https://www.sinomab.com
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
214

Recommended

These two ASX shares are trading at a discount to our fair value.

Morningstar | 24 February 2025

Board members step down over differences on the role of former CEO Richard White.

Roy van Keulen | 24 February 2025

Morningstar's Chief Investment Officer for Asia-Pacific and Director of Personal Finance share their thoughts on the recent RBA rate cut.

Matt Wacher | 21 February 2025

Index	Last price	Change	% Change
All Ordinaries	8,498.00	62.10	-0.73%
CAC 40	8,090.99	63.52	-0.78%
DAX 40	22,425.93	138.37	0.62%
Dow JONES (US)	43,461.21	33.19	0.08%
FTSE 100	8,658.98	0.39	-0.00%
HKSE	23,227.63	113.98	-0.49%
NASDAQ	19,286.93	237.08	-1.21%
Nikkei 225	38,281.45	495.49	-1.28%
NZX 50 Index	12,307.27	224.45	-1.79%
S&P 500	5,983.25	29.88	-0.50%
S&P/ASX 200	8,251.90	56.30	-0.68%
SSE Composite Index	3,367.25	5.77	-0.17%